EUVIMEDEUVIMED entdecken
Crossref

Novel 2‐[thio]acetamide linked quinazoline/1,2,4‐triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers

Ahmed S Abdelkhalek, Hend Kothayer, Mostafa K Soltan, Samy M Ibrahim, Samar S Elbaramawi

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202300627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Ahmed S Abdelkhalek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Antineoplastic Agents, Apoptosis, Quinazolines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel triazoloquinazolines carrying the 2‐[thio]acetamide entity ( 4 and 5a–d ) and triazoloquinazoline/chalcone hybrids incorporating the 2‐[thio]acetamide linker ( 8a–b and 9a–f ) were developed as anticancer candidates. NCI screening of the synthesized compounds at 10 μM concentration displayed growth inhibition not only up to 99.74% as observed for 9a but also a lethal effect could be achieved as stated for compounds 9c (RPMI‐8226 and HCT‐116) and 8b , 9a , and 9e on the HCT‐116 cell line. The antiproliferative activity was determined for the chalcone series on three cell lines: RPMI‐8226, HCT‐116, and MCF‐7. Compounds 8b , 9a , 9b , and 9f were the most active ones. To understand the mechanistic study, the inhibitory effect on the epidermal growth factor receptor (EGFR) kinase was evaluated. The results stated that the activity of compound 8b (IC 50 = 0.07 μM) was near that of the reference drug erlotinib (IC 50 = 0.052 μM) whereas compound 9b (IC 50 = 0.045 μM) was found to be more potent than erlotinib. Both compounds 8b and 9b were selected for cell cycle analysis and apoptotic assays. Moreover, molecular docking results of the selected chalcone hybrids showed high binding scores and good binding affinities especially for 8b and 9b , which were consistent with the biological activity (EGFR).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsAntineoplastic AgentsApoptosisQuinazolinesDrug DesignCell ProliferationTriazolesDrug Screening Assays, AntitumorMolecular Docking SimulationProtein Kinase InhibitorsHumansStructure-Activity RelationshipCell Line, TumorMolecular StructureDose-Response Relationship, DrugChalconesHCT116 CellsAcetamidesMCF-7 CellsChalcone

Stichwörter der Autor:innen

EGFR inhibitorsapoptotic inducerschalconedual activitytriazoloquinazoline hybrids

Substanzen

ErbB ReceptorsAntineoplastic AgentsQuinazolinesEGFR protein, humanTriazolesProtein Kinase InhibitorsChalcones1,2,4-triazoleAcetamidesChalcone

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Pharmacy Program, Oman College of Health Sciences, Muscat, Sultanate of Oman.

Zitieren

APA

Abdelkhalek, A. S., Kothayer, H., Soltan, M. K., Ibrahim, S. M., & Elbaramawi, S. S. (2024). Novel 2‐[thio]acetamide linked quinazoline/1,2,4‐triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300627

Vancouver

Abdelkhalek AS, Kothayer H, Soltan MK, Ibrahim SM, Elbaramawi SS. Novel 2‐[thio]acetamide linked quinazoline/1,2,4‐triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300627

BibTeX
@article{Abdelkhalek2024,
  author = {Abdelkhalek, Ahmed S and Kothayer, Hend and Soltan, Mostafa K and Ibrahim, Samy M and Elbaramawi, Samar S},
  title = {Novel 2‐[thio]acetamide linked quinazoline/1,2,4‐triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202300627}
}
Kostenlos starten →